Vitamin C Re-evaluated: A Direct Inhibitor of the 'Ferro-Aging' Clock

News
#1

FerroAging
FerroAging2752×1536 432 KB

For decades, the free radical theory of aging has driven the consumption of generalized antioxidants with mixed, often disappointing, clinical outcomes. A newly published study fundamentally reframes this paradigm by identifying a specific, targetable biological mechanism termed “ferro-aging”. Unlike acute ferroptosis—a rapid, iron-dependent cellular death pathway—ferro-aging is a chronic, low-grade metabolic program that progressively drives cellular senescence and organismal decline. The data demonstrate that iron naturally accumulates across multiple primate organs over time, catalyzing lipid peroxidation. The central executor of this pro-aging shift is acyl-coenzyme A synthetase long-chain family member 4 (ACSL4).

In a high-throughput screen of iron-homeostasis compounds, vitamin C emerged as the most potent suppressor of this aging axis. Crucially, the researchers identified that vitamin C acts not merely as an electron donor, but as a direct structural inhibitor of the ACSL4 enzyme. Target engagement and molecular docking studies confirmed that vitamin C binds directly to the essential catalytic pocket of ACSL4 (residues Thr278, Ser279, and Thr469), mimicking a loss-of-function mutation and halting the thioesterification of polyunsaturated fatty acids.

To validate physiological relevance, the research team conducted a 40-month intervention in aged cynomolgus monkeys. Daily oral supplementation of vitamin C (30 mg/kg, equivalent to approx. 700mg for a human) resulted in a systemic reversal of biological age as measured by multi-omic clocks, encompassing DNA methylation, transcriptomics, and metabolomics. The intervention reversed age-related brain atrophy, restored structural connectivity in the parietal cortex, and improved systemic metabolic markers including triglyceride and insulin levels. This research elevates vitamin C from a generic health supplement to a targeted metabolic modulator of a highly specific lipid-aging mechanism, offering actionable insights for longevity interventions.

In total, the 40-month long oral vitamin C intervention in aged cynomolgus monkeys demonstrated a calculated biological age reversal of three to seven years—representing 10% to 20% of the species’ maximum lifespan—across epigenetic, transcriptomic, and metabolomic clocks, alongside structural brain preservation and metabolic improvements. The most pronounced age-reversal effects were observed in highly metabolic and supportive cell types, such as hippocampal microglia and pancreatic beta cells.

Source:

Related Reading:

8 Likes
#2

Study Design Specifications

  • Type: The study utilized robust in vitro (human cellular models) and in vivo (mouse and non-human primate) models.

  • Subjects (Monkeys): The primate arm utilized cynomolgus monkeys of Southeast Asian origin. The young control group (Y-Ctrl) was 4-5 years old (N=10-12). The old control group (O-Ctrl) was 16-20 years old (N=4-10). The old intervention group (O-VC) was 16-20 years old (N=5). Sex was not explicitly restricted in the primate text provided, though models indicate both male and female sampling.

  • Subjects (Mice): Rodent data were derived from C57BL/6J mice (male, N=11-23 per group) and Zmpste24-knockout progeroid mice (male, N=4-16 per group).

Novelty

This paper functionally separates chronic “ferro-aging” from acute ferroptosis, establishing it as a conserved primate aging mechanism. The most significant novelty is the identification of vitamin C not merely as a free-radical scavenger, but as a direct, structural enzyme inhibitor of ACSL4. By identifying the specific binding pocket (T278/S279/T469), this paper provides a highly specific pharmacological mechanism for an extensively studied, widely available compound.

Critical Limitations

  • Translational Uncertainty (Sample Size): The in vivo primate intervention cohort is exceedingly small (N=5 for the O-VC group). Drawing population-level metabolic or neurological conclusions from five subjects introduces significant risk of Type I errors [Confidence: High].
  • Methodological Weaknesses (Endpoint Data): While epigenetic and transcriptomic clocks were reversed, the absence of longitudinal survival data leaves the ultimate impact on maximum lifespan unknown [Confidence: High]. Biological age reversal on a clock does not guarantee proportional extension of chronological lifespan.
  • Effect-Size Uncertainty (Dosing): The study utilized 30 mg/kg/day in cynomolgus macaques (approx. 120 mg/day for a 4kg animal). Translating this dose to humans suggests a highly attainable, low-end intervention compared to typical liposomal or IV biohacking protocols [Confidence: Medium]. It remains unclear if higher doses would yield increased ACSL4 inhibition or trigger hormetic ceiling effects.
  • Missing Data: The study does not provide exhaustive mapping of potential off-target binding interactions of vitamin C across the broader proteome, nor does it quantify if ACSL4 inhibition alters essential, non-pathological PUFA metabolism in young, healthy phenotypes [Confidence: High].

Claims & External Verification

Here is the rigorous external verification of the core claims made in the study.

Claim 1: Iron accumulation increases with age, driving lipid peroxidation and cellular senescence.

  • External Verification: The foundational link between age-related iron accumulation, oxidative stress, and physiological decline is well-documented in the literature. However, the specific framing of this sequence as “ferro-aging” acting as a primary, systemic driver of organismal aging is a recent hypothesis.
  • Evidence Level: Level C / D (Human Observational / Pre-clinical). While human observational data confirms tissue iron increases with age, the mechanistic leap that this strictly dictates the rate of aging relies heavily on cell and animal models.
  • Translational Gap: Yes. Causality is primarily established in non-human models.
  • Citation: Ferroptosis and Senescence: A Systematic Review (2023)

Claim 2: ACSL4 is the central enzymatic executor driving iron-induced lipid peroxidation and ferroptosis.

  • External Verification: External literature robustly supports ACSL4’s role as the primary enzyme that esterifies polyunsaturated fatty acids (PUFAs) into cellular membranes, setting the stage for iron-catalyzed lipid peroxidation and subsequent ferroptosis.
  • Evidence Level: Level D (Pre-clinical / In vitro). [FLAG: High reliance on pre-clinical models]. The metabolic pathways of ACSL4 are universally mapped via in vitro and mouse models, predominantly within oncology and ischemia-reperfusion research.
  • Translational Gap: Yes. The exact magnitude of ACSL4’s role in driving systemic human aging—outside of acute ferroptotic cell death—remains unproven in clinical trials.
  • Citation: ACSL4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis (2025)

Claim 3: Vitamin C acts as a direct, structural inhibitor of the ACSL4 enzyme.

  • External Verification: This is the novel anchor claim of the 2026 study. External literature generally characterizes Vitamin C as a water-soluble antioxidant, a cofactor for collagen synthesis, and occasionally as a pro-oxidant that induces ferroptosis in cancer cells. The assertion that it directly binds the T278/S279/T469 pocket of ACSL4 to halt its enzymatic function is entirely new to this publication and lacks external replication.
  • Evidence Level: Level D (Pre-clinical). [FLAG: High reliance on single-study pre-clinical data].
  • Translational Gap: Yes.
  • Citation: Vitamin C inhibits ACSL4 to alleviate ferro-aging in primates (2026)

Claim 4: Vitamin C activates the Nrf2 antioxidant pathway to bolster defenses against oxidative stress and ferro-aging.

  • External Verification: External studies confirm that Vitamin C can modulate the Nrf2 signaling cascade. However, the literature is highly context-dependent. In healthy or stressed normal tissues, it can upregulate Nrf2 to boost endogenous antioxidant enzymes (like HO-1). Conversely, in oncology models, high-dose Vitamin C has been shown to inhibit Nrf2 to sensitize tumors to death.
  • Evidence Level: Level D (Pre-clinical / Animal models). [FLAG: High reliance on pre-clinical models].
  • Translational Gap: Yes. While Nrf2 is a conserved pathway, the specific threshold at which Vitamin C activates versus suppresses this pathway in human aging is not well-defined.
  • Citation: Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway (2024)

Claim 5: Long-term Vitamin C supplementation (30 mg/kg/day) reverses multi-omic biological age, mitigates brain atrophy, and improves metabolic health.

  • External Verification: While decades of Level B (Human RCTs) and Level A (Meta-analyses) data exist regarding Vitamin C supplementation, the results for extending human lifespan or preventing cognitive decline are notoriously mixed and often clinically insignificant. The highly specific claim of reversing multi-omic clocks and restoring structural brain connectivity relies exclusively on the cynomolgus monkey data presented in this 2026 paper.
  • Evidence Level: Level D (Pre-clinical / Non-human primates). [FLAG: Strict reliance on animal data for systemic aging reversal claims].
  • Translational Gap: Yes. Non-human primates are excellent models, but 40 months of supplementation in macaques cannot be directly extrapolated to human clinical outcomes without targeted RCTs verifying biological age reversal.
  • Citation: Vitamin C inhibits ACSL4 to alleviate ferro-aging in primates (2026)
1 Like
#3

Actionable Intelligence

The Translational Protocol (Rigorous Extrapolation)

  • Human Equivalent Dose (HED):
    • Calculation: Using the FDA Guidance for Estimating the Maximum Safe Starting Dose, the translation from Cynomolgus monkey to adult human (assuming 60 kg) utilizes Body Surface Area (BSA) normalization factors (Km). Monkey Km = 12; Human Km = 37.
    • Math: 30 mg/kg * (12 / 37) = 9.73 mg/kg.
    • Human Dose: For a standard 70 kg adult, the target HED is roughly 680 mg/day. This falls well within standard supplemental ranges and avoids the necessity of intravenous administration.
  • Pharmacokinetics (PK/PD):
    • Bioavailability: Vitamin C exhibits dose-dependent, active transport kinetics via SVCT1 and SVCT2 receptors. At an oral dose of 500–1000 mg, bioavailability is approximately 70% to 80%, but it steeply declines at higher doses due to tissue saturation and renal clearance. Peak plasma concentrations plateau at approximately 70–80 micromolar.
    • Half-life: Highly variable depending on baseline plasma levels, typically ranging from 10 to 20 hours. Reference: NIH ODS.
  • Safety & Toxicity:
    • LD50: The oral LD50 in rats is 11,900 mg/kg.
    • NOAEL / Upper Limit: The established Tolerable Upper Intake Level (UL) in humans is 2,000 mg/day. Toxicity at this level is generally limited to osmotic diarrhea and gastrointestinal disturbances.
    • Phase I Safety Profile: Vitamin C is generally recognized as safe (GRAS). However, high-dose continuous supplementation increases urinary oxalate excretion, elevating the risk of calcium oxalate kidney stones in susceptible individuals.
    • CYP450 / Liver / Kidney: No significant CYP450 inhibition or induction. Primary clearance is renal. Extreme doses in patients with pre-existing renal impairment (or G6PD deficiency) can induce hemolysis or acute oxalate nephropathy.

Biomarker Verification To verify target engagement of ACSL4 inhibition in a clinical or biohacking setting, track the following downstream lipidomic and oxidative markers in plasma or PBMCs (Peripheral Blood Mononuclear Cells):

  • Direct ACSL4 Metabolites: Reduced levels of Arachidonoyl-CoA (20:4-CoA) and Adrenoyl-CoA (22:4-CoA).
  • Downstream Phospholipids: Decreased polyunsaturated phosphatidylcholines (PC) and phosphatidylethanolamines (PE), specifically PE 38:4 and PE 36:4.
  • Lipid Peroxidation End-Products: Reduced systemic malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE).

Feasibility & ROI

  • Sourcing: Over-the-counter (OTC). Ubiquitously available as ascorbic acid.
  • Cost vs. Effect: Monthly cost for a high-quality 500-1000 mg/day supplement is under $10. Given the minimal cost and high safety profile, the ROI is massive if the ACSL4 inhibition translates clinically to humans. It is a highly practical addition to a longevity protocol.

Part 5: The Strategic FAQ

1. If Vitamin C is a potent ACSL4 inhibitor, why have previous large-scale, high-dose longevity and cardiovascular RCTs failed to show significant lifespan extension? Answer: Previous trials viewed Vitamin C purely as a systemic antioxidant rather than a targeted enzyme inhibitor. It is highly probable that typical supplemental dosing achieves plasma saturation (approx. 80 micromolar) but fails to reach the intracellular concentrations required to competitively inhibit the ACSL4 binding pocket across all tissue types, particularly in organs with high lipid turnover. Furthermore, generic antioxidant trials often fail because they indiscriminately suppress necessary hormetic ROS signaling.

2. Does Vitamin C have a sufficient binding affinity (Kd) to outcompete endogenous polyunsaturated fatty acids for the ACSL4 active site at physiological concentrations? Answer: The paper’s computational docking and in vitro assays suggest successful competition, but in vivo enzymatic kinetics are missing. Since humans actively regulate plasma Vitamin C, achieving the necessary intracellular stoichiometry to outcompete abundant arachidonic acid in lipid-rich environments (like the brain) without intravenous administration remains a critical knowledge gap.

3. The macaques received 30 mg/kg/day, but their baseline diet already contained roughly 150 mg/day. Did this study just cure captive primate scurvy/sub-clinical deficiency? Answer: Captive primates require exogenous Vitamin C, just like humans. While the authors claim the control group was not deficient, doubling the baseline intake may simply optimize a baseline physiological deficit rather than inducing a novel, supra-physiological geroprotective state. We need data comparing this dose to a known, strictly optimized baseline cohort.

4. ACSL4 is essential for normal membrane remodeling and cellular function. Does chronic, long-term inhibition risk membrane instability or impaired cellular repair? Answer: Yes. Complete knockout of ACSL4 is often embryonically lethal or highly deleterious in pre-clinical models. The goal is partial attenuation, not total ablation. Chronic, high-level inhibition could theoretically impair necessary inflammatory responses, macrophage activation, and membrane repair processes.

5. How does Vitamin C interact with Rapamycin, considering both modulate lipid metabolism and cellular senescence? Answer: Rapamycin inhibits mTOR, triggering autophagy and altering lipid profiles (often causing transient hyperlipidemia). ACSL4 inhibition by Vitamin C targets the downstream consequence of lipid membrane oxidation. There is no acute pharmacological conflict, and they likely act synergistically by targeting distinct hallmarks of aging (nutrient sensing vs. oxidative macromolecular damage).

6. Metformin relies on mild complex I inhibition and transient ROS generation to trigger AMPK. Will high-dose Vitamin C blunt this effect? Answer: This is a known translational risk. High-dose antioxidants (specifically Vitamins C and E) have been shown in multiple human trials to blunt the insulin-sensitizing and mitochondrial-biogenesis effects of exercise and potentially metformin by quenching the necessary ROS signal. Timing doses away from exercise and metformin administration is highly recommended. Reference: Antioxidants prevent health-promoting effects of physical exercise in humans (2009).

7. Does this ACSL4 inhibition mechanism interfere with SGLT2 inhibitors or Acarbose? Answer: No direct pharmacokinetic or pharmacodynamic conflicts exist. SGLT2 inhibitors (e.g., empagliflozin) act hemodynamically and metabolically via the kidneys, while acarbose acts in the gut. Vitamin C’s intracellular action on ACSL4 should run parallel without interference.

8. Can Vitamin C cross the blood-brain barrier in sufficient quantities to reverse the neuro-degeneration (brain atrophy) observed in the primate models? Answer: Vitamin C crosses the blood-brain barrier via the SVCT2 transporter in its reduced form, and via GLUT1 in its oxidized form (dehydroascorbic acid), where it is then reduced back. The brain maintains some of the highest concentrations of Vitamin C in the body, making targeted ACSL4 inhibition in neural tissue theoretically feasible with oral dosing.

9. The study highlights reduced cGAS-STING activation. Is this a direct effect of Vitamin C or downstream of ACSL4 inhibition? Answer: It is downstream. ACSL4 drives lipid peroxidation, which damages mitochondrial and nuclear membranes, leading to cytosolic DNA leakage. The cGAS-STING pathway senses this misplaced DNA and triggers sterile inflammation. By halting the upstream membrane damage, Vitamin C indirectly silences the cGAS-STING inflammaging alarm.

10. What specific human data is required to move this from a “promising primate study” to a “verified human longevity protocol”? Answer: We need a placebo-controlled RCT in middle-aged to older adults tracking the specific lipidomic biomarkers identified above (20:4-CoA, PE 38:4), alongside epigenetic clock analysis, over a 12-to-24-month period. Until we see targeted ACSL4 metabolite reduction in human plasma, this remains an informed hypothesis.

3 Likes
#4

Follow-on Prompt:

Try to quantify the effect size of the vitamin C intervention in terms of aging biomarkers.

Gemini 3 Pro Response:

The paper quantifies the effect size of a 40-month oral vitamin C intervention (30 mg/kg/day) in aged cynomolgus monkeys by measuring the difference in predicted biological age between the treated group (O-VC) and the age-matched control group (O-Ctrl).

It is necessary to frame these numbers accurately: the data represent cynomolgus monkey years. With a maximum lifespan of roughly 30 to 35 years for this species, a reversal of 3 to 7 biological years on a computational clock represents a 10% to 20% shift relative to total maximum lifespan.

Multi-Omic Biological Age Reversal

The intervention demonstrated biological age reduction across established epigenetic, transcriptomic, and metabolomic clocks. The effect sizes below are expressed as the absolute difference in predicted age (in years).

Omics Modality Tissue / System Age Difference (Years)
Epigenomic (DNAm) Brain (Frontal Lobe) -5.91
Brown Adipose Tissue -4.44
Skeletal Muscle (Quadriceps) -4.41
Skin (Abdomen) -4.17
Aorta -3.77
Kidney -3.38
Transcriptomic Visceral Adipose Tissue (Pancreas) -5.67
Adrenal Gland -5.24
Brain (Hippocampus) -4.91
Subcutaneous Adipose Tissue -4.40
Skin (Hand) -4.20
Stomach -4.14
Kidney (Medulla) -4.10
Metabolomic Plasma -3.48

Cell-Type-Specific Transcriptomic Reversals

Single-nucleus and single-cell RNA sequencing showed that specific highly metabolic and supportive cell types experienced age-reversal shifts that outpaced the bulk tissue averages.

  • Hippocampus:
    • Microglia: -7.39 years
    • Oligodendrocyte Precursor Cells (OPCs): -5.55 years
    • Oligodendroglia: -4.74 years
  • Pancreas:
    • Beta cells: -6.97 years
    • Ductal cells: -6.85 years
    • Alpha cells: -6.12 years

Physiological and Structural Effect Sizes

The authors did not provide absolute percentage changes for all physical traits, but the structural and metabolic endpoints demonstrated quantifiable mitigation of age-related phenotypes:

  • Brain Atrophy: Reversed age-related cortical surface area decline in the frontal lobes, specifically enlarging four regions of the orbital frontal cortex.
  • Neural Connectivity: Restored structural connectivity in 9 out of 18 posterior parietal cortex regions that demonstrated age-related degradation in the control group.
  • Metabolic Markers: Attenuated the age-associated increase in plasma triglycerides and total bile acids, curbed age-associated hyperinsulinemia, and reduced expansions in total and visceral fat areas.

Critical Evaluation of Effect Size

  1. Algorithmic Relativity: These effect sizes are mathematical derivations from machine-learning models trained specifically on the gene expression and methylation patterns of this exact macaque cohort. They measure predicted age based on a statistical model, not functional vitality or actual tissue age.
  2. Lack of Hard Endpoints: The study lacks chronological mortality data. A 5.9-year reversal in frontal lobe DNA methylation does not equate to a 5.9-year extension in chronological lifespan. It indicates a shift in methylation patterns toward a younger profile, which may or may not translate to delayed mortality.
  3. Translational Uncertainty: Extrapolating a 5-year epigenetic age reversal from a macaque to a human is non-linear and highly speculative. Furthermore, the intervention group consisted of only 5 monkeys. Generating definitive population-level effect sizes from an N of 5 introduces massive statistical vulnerability. Human randomized controlled trials with robust sample sizes are required to verify if these biological clock reversals translate to human physiology.
2 Likes
#5

So Vitamin C is great for reducing aging. Excellent!

I take 1 g of XR Vitamin C daily in the morning. I beleive XR is important so that your body has a continual source of Vitamin C throughout the day and it all doesn’t get flushed in one large dose.

Also, love citrus.

2 Likes
#6

Humans have lost the ability to manufacture their own Vitamin C and so we are totally dependent on diet.
Cynomolgus monkeys alternatively (according to the DuckDuck AI) are able to manufacture their own Vitamin C.
This makes the dosage translation to humans considerably more problematic,
It’s not clear to me how to adjust the monkey to human dosage to take this biological difference into account.
Humans may need considerably more vitamin C for the purported benefit than do Cynomolgus monkeys.

1 Like
#7

From Google Gemini 3 Pro:

Fact Check: Vitamin C Synthesis in Cynomolgus Monkeys

Claim: Humans have lost the ability to manufacture their own Vitamin C, but Cynomolgus monkeys are able to manufacture their own.

Status: False.

Correction: Your AI source (DuckDuck AI) provided incorrect information. Cynomolgus monkeys (Macaca fascicularis, also known as crab-eating or long-tailed macaques) cannot synthesize their own vitamin C.

Like humans, apes, and all other Old World and New World monkeys (the entire Haplorrhini suborder), cynomolgus monkeys share an identical evolutionary mutation: the inactivation of the L-gulonolactone oxidase (GULO) gene. This enzyme is strictly required for the final step of ascorbic acid biosynthesis from glucose. Because this gene is a non-functional pseudogene in macaques, they are entirely dependent on dietary vitamin C to prevent scurvy and maintain physiological function. Among primates, only the more distant Strepsirrhini suborder (such as lemurs) retain the ability to synthesize vitamin C endogenously.

To compensate for this shared genetic inability to synthesize vitamin C, both humans and macaques evolved a shared compensatory mechanism: the expression of the Glut1 transporter on red blood cells, which actively recycles oxidized vitamin C (dehydroascorbic acid) back into the tissue pool.

1 Like
#8

Thanks for clearing that up.
Welcome to our world where the veracity of information depends on the AI source and on the phrasing of the question
Recent reports that AIs make their answers to “satisfy” their clients are not heartening
A lesson to us all.

3 Likes
#9

If this applied to humans, we’d have seen good outcomes ages ago. There have been a lot of trials with a variety of vit. C doses and the results have been underwhelming at best. Show me these results in humans and not monkeys.

Undoubtedly maintaining good vit. C status through diet and maybe modest supplementation is a good idea. But a youth serum? Very doubtful.

1 Like
#10

The following procurement data identifies the top ten lowest-cost sources for extended-release (sustained/timed-release) Vitamin C supplements in the 500 mg to 1000 mg range, currently available for shipping within the United States. Prices are subject to real-time vendor fluctuations but represent the most current market data.

Cost Analysis: Extended-Release Vitamin C

Rank Product/Brand Name Vendor Total Weight (Original Unit & Grams) Total Price (USD) Cost Per 1 gram
1 NOW Foods, C-1000 With Rose Hips, Sustained Release, 250 Tablets iHerb 250 Tablets (1000 mg each)
Total: 250g		 USD 19.59 USD 0.078
(19.59 / 250)
2 21st Century, Vitamin C, Prolonged Release, 1,000 mg, 110 Tablets iHerb 110 Tablets (1000 mg each)
Total: 110g		 USD 9.99 USD 0.091
(9.99 / 110)
3 NOW Foods, C-1000 With Rose Hips, Sustained Release, 100 Tablets iHerb 100 Tablets (1000 mg each)
Total: 100g		 USD 9.17 USD 0.092
(9.17 / 100)
4 Natural Factors, Vitamin C, Time Release, 1,000 mg, 180 Tablets iHerb 180 Tablets (1000 mg each)
Total: 180g		 USD 16.77 USD 0.093
(16.77 / 180)
5 Vitacost Vitamin C-1000 Complex Including Citrus Bioflavonoids, 100 Slow Release Tablets Vitacost 100 Tablets (1000 mg each)
Total: 100g		 USD 9.99 USD 0.100
(9.99 / 100)
6 Solaray, Timed Release Vitamin C with Rose Hips & Acerola, 1,000 mg, 250 VegCaps iHerb 250 Capsules (1000 mg each)
Total: 250g		 USD 32.09 USD 0.128
(32.09 / 250)
7 21st Century, Vitamin C, Prolonged Release, 500 mg, 110 Tablets iHerb 110 Tablets (500 mg each)
Total: 55g		 USD 7.99 USD 0.145
(7.99 / 55)
8 Solaray, Timed Release Vitamin C with Rose Hips & Acerola, 1,000 mg, 100 VegCaps iHerb 100 Capsules (1000 mg each)
Total: 100g		 USD 15.99 USD 0.160
(15.99 / 100)
9 Solaray, Vitamin C Timed Release, 500 mg, 100 Capsules Vitacost 100 Capsules (500 mg each)
Total: 50g		 USD 11.49 USD 0.230
(11.49 / 50)
10 Nature Made, Vitamin C with Rose Hips Timed Release, 1000 mg, 60 Tablets Vitacost 60 Tablets (1000 mg each)
Total: 60g		 USD 13.79 USD 0.230
(13.79 / 60)

Shipping Logistics

  • iHerb: Offers free standard shipping on domestic USA orders exceeding USD 30.00. For orders below this threshold, flat-rate shipping typically costs USD 5.00 depending on exact geographic location.
  • Vitacost: Provides free standard shipping on domestic USA orders over USD 49.00. Orders failing to meet this minimum incur a flat rate of USD 7.99 to USD 9.99 depending on the carrier utilized.
1 Like
#11

I use the NOW brand without rose hips. But maybe I should add them in?

Taking extended-release Vitamin C with rose hips combines a specialized delivery method with natural “helper” compounds to maximize how much vitamin your body actually keeps and uses.

While standard Vitamin C is often absorbed quickly and then flushed out through urine within hours, this combination is designed for 24-hour protection and better cellular efficiency.

  1. Sustained Blood Levels
    Extended-release (or “timed-release”) tablets are formulated with special coatings or matrix systems that dissolve slowly in the digestive tract.

Avoids the “Peak and Crash”: Instead of a massive spike that triggers your kidneys to excrete the “excess” vitamin, these tablets provide a steady, lower-level drip into the bloodstream.

Longer-Lasting Defense: Pharmacokinetic studies show that sustained-release formulas can maintain high plasma concentrations for 12 to 24 hours, whereas immediate-release levels typically drop back to baseline much sooner.

  1. Synergistic Absorption from Rose Hips
    Rose hips are not just a Vitamin C source; they contain bioflavonoids (like quercetin) that work as natural catalysts.

Enhanced Bioavailability: These natural compounds help transport Vitamin C across cell membranes more effectively than synthetic ascorbic acid alone.
Protection from Oxidation: The antioxidants in rose hips help stabilize the Vitamin C molecule, preventing it from degrading before your cells can use it.

  1. Better Digestive Tolerance
    High doses of standard Vitamin C (like 1,000mg all at once) can be acidic and often cause stomach upset, bloating, or diarrhea.

Gentle Delivery: By spreading the release over several hours, the extended-release format reduces the “acid hit” to the stomach lining, making it a better choice for those with sensitive digestion.

  1. Support for All-Day Collagen & Immunity
    Because Vitamin C is a critical cofactor for collagen synthesis, having it present in your system consistently throughout the day (rather than just for 2 hours after a pill) can provide better support for skin elasticity and joint repair.
1 Like
#12

Ridiculous. I don’t want to take more than 100mg tablets of vit. C. You’d be surprised how hard it is to find such. I’ve only been able to find one GNC brand and one NaturesPlus. Wonder what your AI would find. Even harder to find: vitamin B complex, where none of the vitamin Bs are over 100% RDA - good luck with that, the closest I found was Nature Made that has most at 125% RDA or more. Insane, that there would be no market demand for this, instead we have these crazy supraphysiological doses you’d never consume in food in a day.

#13

I haven’t got the references to hand, but AIUI there are disadvantages from taking Vitamin C every day as this undermines endogenous antioxidants.

1 Like
#14

For better or worse, I have taken supplemental vitamin C daily for 61 years.

4 Likes
#15

“Cynomolgus monkeys are frequently used in biomedical research because researchers believe these monkeys are the ideal models due to the 90-93% genetic similarity to and recent evolutionary divergence from humans.”

The results of testing in monkeys are more likely to be translatable to humans than those from mouse studies.

Linus Paul’s promotion of high doses of vitamin C may have some merit.

5 Likes
#16

On my soap box again…

“If you wait until you are ready, it is almost certainly too late.”
~ Seth Godin

“And may contribute to premature expiration”
~Joseph

“When writing the story of your life, do not let anyone else hold the pen.” ~Jack Kerouac

2 Likes
#17

The assertion that chronic, high-dose Vitamin C supplementation undermines endogenous antioxidant capacity is fundamentally accurate and represents a critical paradigm shift in modern gerontology. While Vitamin C is an essential micronutrient, treating it as a ubiquitous, high-dose systemic shield fundamentally misinterprets the role of oxidative stress in human longevity.

Here is the direct, biochemical reality of how exogenous antioxidants interact with endogenous cellular defense systems.

The Mitohormesis Disruption

For decades, the “free radical theory of aging” dictated that all Reactive Oxygen Species (ROS) were cellular damage agents that needed to be neutralized. This is now considered outdated. Current longevity science operates on the principle of mitohormesis—the concept that low-to-moderate bursts of oxidative stress are strictly required to signal for cellular repair and metabolic adaptation.

When the body experiences a transient spike in ROS (induced by exercise, fasting, or mild mitochondrial uncoupling), it acts as a signaling molecule. This spike activates the Keap1-Nrf2-ARE signaling pathway. Nrf2 is the master transcription factor that upregulates the body’s endogenous antioxidant enzymes, including superoxide dismutase (SOD), catalase, and glutathione peroxidase.

If you flood the system with high doses of a strong exogenous electron donor like Vitamin C, you quench the initial ROS spike. By neutralizing the signal, you prevent the activation of Nrf2. The cell never receives the biological instruction to build its own, vastly more powerful, endogenous defense network.

Clinical Evidence of Blunted Adaptations

The most robust human clinical data demonstrating this detrimental effect comes from exercise physiology. Exercise is the most potent, verified longevity intervention available, functioning precisely through hormetic ROS generation.

A landmark human randomized controlled trial by Ristow et al. (2009) demonstrated that daily supplementation with Vitamin C (1000 mg) and Vitamin E (400 IU) completely abolished the health-promoting effects of physical exercise. Specifically, the antioxidant cocktail prevented the exercise-induced upregulation of PPAR$\gamma$ and PGC-1$\alpha$ (critical regulators of mitochondrial biogenesis) and blocked the expected improvements in insulin sensitivity.

Subsequent clinical analyses have corroborated that chronic antioxidant megadosing blunts skeletal muscle hypertrophy, endurance adaptations, and vasodilation.

The Longevity Paradox: Reconciling the Macaque Data

We must reconcile this hormetic blunting with the recent 2026 data identifying Vitamin C as a potent, geroprotective inhibitor of ACSL4-driven “ferro-aging.”

  1. Dose and Context: The cynomolgus macaque data utilized a Human Equivalent Dose (HED) of approximately 680 mg/day for a standard adult. This is sufficient to saturate plasma levels and act as an enzyme inhibitor without reaching the extreme “megadose” thresholds (e.g., 2,000–5,000+ mg) often used in biohacking protocols that aggressively quench all systemic ROS.
  2. Tissue-Specific vs. Systemic Action: In the context of ferro-aging, Vitamin C is acting via direct structural binding to the ACSL4 catalytic pocket to prevent toxic lipid peroxidation, rather than just acting as a generalized systemic free-radical scavenger.
  3. Age as a Variable: Hormetic capacity declines with age. A younger organism thrives on ROS signaling to build resilience. In a heavily aged, frail organism (like the 16-to-20-year-old macaques), the endogenous Nrf2 system may already be irreparably degraded, and chronic iron accumulation may result in a continuous, pathological ROS leakage rather than a healthy, transient signaling spike. In advanced age, suppressing this toxic “ferro-aging” leak may provide a net positive ROI, whereas the same suppression in a healthy 30-year-old would just blunt physical adaptations.

Actionable Strategic Insights

To leverage the ACSL4-inhibiting benefits of Vitamin C while preserving endogenous mitohormesis, consider the following protocols:

  • Avoid the Post-Workout Window: Never consume high-dose Vitamin C within 4 hours before or after a strenuous physical training session. Allow the acute ROS spike to trigger Nrf2 and mitochondrial biogenesis unhindered.
  • Cap the Dosage: Plasma saturation of Vitamin C in humans is generally achieved at approximately 400 to 500 mg/day. Supplementing beyond 1,000 mg/day provides negligible additional enzyme inhibition while significantly increasing the risk of over-scavenging hormetic ROS signals and increasing renal oxalate burden.
  • Pulsing vs. Chronic Use: Align exogenous antioxidant use with periods of high, unavoidable oxidative distress (e.g., illness, sleep deprivation, or heavy travel), but cycle off during periods of optimized metabolic training to allow endogenous systems to stress-test and adapt.

Identified Knowledge Gaps

  • Human Thresholds: The exact pharmacological threshold at which Vitamin C transitions from saturating the ACSL4 binding pocket to systemically blunting human Nrf2 activation remains unquantified in vivo.
  • Geroprotector Interactions: We lack clinical data on how Vitamin C interacts with mild mitochondrial inhibitors like metformin, which also rely on transient ROS generation for their AMPK-activating effects.
#18

Apparently, a higher dosage would apply only to old folks like me, reaching the very aged category.

2 Likes
#19

Yes, and we want to take it 4 hours after your work-out session.

2 Likes
#20

I have vitamin C twice a week

1 Like